Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Murciano-Goroff YR, Hollebecque A, Heist RS, Cassier PA, Han JY, Kim SY, Sabari JK, Tosi D, Sacher A, Burns TF, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor JN, Nagasaka M, You AX, McNeely SC, Peter R, Fink A, Chen A, Oxnard GR, Willard MD, Kuboki Y, Koyama T

Open source

DOI: 10.1038/s41467-026-69943-7
Published: 2026 Mar 12
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-69943-7,
  title = {Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.},
  author = {Murciano-Goroff YR and Hollebecque A and Heist RS and Cassier PA and Han JY and Kim SY and Sabari JK and Tosi D and Sacher A and Burns TF and Shimizu T and Reddy Ammakkanavar N and Spira A and Gomez-Roca C and Patnaik A and Cosman R and Bodor JN and Nagasaka M and You AX and McNeely SC and Peter R and Fink A and Chen A and Oxnard GR and Willard MD and Kuboki Y and Koyama T},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-69943-7},
  url = {https://doi.org/10.1038/s41467-026-69943-7}
}

RIS

TY  - JOUR
TI  - Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.
AU  - Murciano-Goroff YR
AU  - Hollebecque A
AU  - Heist RS
AU  - Cassier PA
AU  - Han JY
AU  - Kim SY
AU  - Sabari JK
AU  - Tosi D
AU  - Sacher A
AU  - Burns TF
AU  - Shimizu T
AU  - Reddy Ammakkanavar N
AU  - Spira A
AU  - Gomez-Roca C
AU  - Patnaik A
AU  - Cosman R
AU  - Bodor JN
AU  - Nagasaka M
AU  - You AX
AU  - McNeely SC
AU  - Peter R
AU  - Fink A
AU  - Chen A
AU  - Oxnard GR
AU  - Willard MD
AU  - Kuboki Y
AU  - Koyama T
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-69943-7
UR  - https://doi.org/10.1038/s41467-026-69943-7
ER  -

APA

YR, M., A, H., RS, H., PA, C., JY, H., SY, K., JK, S., D, T., A, S., TF, B., T, S., N, R. A., A, S., C, G., A, P., R, C., JN, B., M, N., AX, Y., SC, M., R, P., A, F., A, C., GR, O., MD, W., Y, K., & T, K. (2026). Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.. Nature communications. https://doi.org/10.1038/s41467-026-69943-7

Source records

pubmed · retrieved 2026-09-26T05:34:30.662Z